In a 46‑year‑old woman with invasive ductal carcinoma stage IIIb who has had a modified radical mastectomy, completed ACT chemotherapy, ER‑positive/PR‑positive, HER2‑negative, and whose menopausal status is uncertain, can goserelin be started while awaiting follicle‑stimulating hormone and estradiol levels?

Yes, you can start goserelin now without waiting for FSH and estradiol results.

In a 46-year-old woman with stage IIIB ER+/PR+ HER2-negative breast cancer who has completed chemotherapy, goserelin should be initiated immediately as part of adjuvant endocrine therapy, regardless of whether menopausal status has been confirmed. The NCCN 2024 guidelines explicitly support starting ovarian function suppression (OFS) with GnRH agonists like goserelin concurrently with or immediately after chemotherapy completion 1.

Why Starting Goserelin Now Is Appropriate

High-Risk Disease Requires Prompt Endocrine Therapy

Your patient has stage IIIB disease with node-positive status (implied by stage), which places her in the high-risk category for recurrence. The NCCN guidelines specifically recommend that high-risk premenopausal patients with hormone receptor-positive breast cancer should receive ovarian suppression plus endocrine therapy based on the SOFT and TEXT trials, which demonstrated an 8-year disease-free survival of 85.4% with OFS + tamoxifen versus 80.2% with tamoxifen alone 1.

Post-Chemotherapy Timing Is Optimal

The NCCN guidelines state that OFS should be initiated:

• "With start of chemotherapy (neoadjuvant or adjuvant)" or
• "Concurrent with RT or upon completion" 1

Since your patient has completed ACT chemotherapy, this is precisely the appropriate time to start goserelin. Delaying for laboratory confirmation serves no therapeutic benefit and may unnecessarily postpone critical adjuvant therapy.

Menopausal Status Cannot Be Determined While Receiving OFS

Here's the critical point: "Menopausal status cannot be determined while receiving OFS" 1. Once you start goserelin, the FSH and estradiol levels will be suppressed anyway, making those tests uninformative for determining baseline menopausal status. The guidelines recommend monitoring estradiol and FSH/LH levels:

• In women under 60 who are amenorrheic ≤12 months
• After chemotherapy (which applies to your patient)
• Prior to next dose of GnRH agonist, particularly in women under age 45 1

Age 46 Post-Chemotherapy: Assume Premenopausal Until Proven Otherwise

At age 46, even after chemotherapy-induced amenorrhea, your patient should be treated as premenopausal for therapeutic purposes. The ASCO 2016 metastatic breast cancer guidelines emphasize that premenopausal women should receive ovarian suppression, and caution that "suppression of ovarian production of estrogen may be incomplete, particularly when combined with AIs" 2. This is even more relevant in the adjuvant setting where you want to ensure complete ovarian suppression.

Practical Management Algorithm

Immediate Actions:

1. Start goserelin 3.6 mg SC every 4 weeks (or 10.8 mg every 12 weeks if available) 1, 3
2. Initiate tamoxifen concurrently or consider an aromatase inhibitor after 1-2 cycles of goserelin once estradiol reaches postmenopausal range 1
3. Order baseline FSH and estradiol now (before first goserelin dose if possible, but don't delay treatment)

Monitoring Strategy:

• Check estradiol levels prior to the next goserelin dose (particularly important in women under 45, but reasonable at age 46) 1
• Use a high-sensitivity estradiol assay to confirm adequate suppression to postmenopausal levels 2
• If estradiol is not adequately suppressed, consider increasing frequency or dose of goserelin 3
• Monitor for return of menses or menopausal symptoms

Duration of Treatment:

• 5 years of OFS is optimal based on SOFT and TEXT trials 1
• Minimum 2 years should be completed 1

Important Caveats

Aromatase Inhibitor Considerations

If you plan to use an aromatase inhibitor (AI) rather than tamoxifen:

• Wait 1-2 cycles of goserelin to ensure estradiol suppression to postmenopausal range before starting the AI 1
• AIs can stimulate ovarian function in premenopausal women, potentially causing incomplete suppression 1, 2
• Never use an AI alone without confirmed ovarian suppression 4, 5, 4

Monitoring for Incomplete Suppression

The ASCO guidelines warn that ovarian suppression may be incomplete with GnRH agonists, especially when combined with AIs 2. Watch for:

• Vaginal bleeding (patient should contact you immediately) 1
• Return of menopausal symptoms suggesting persistent ovarian function
• Elevated estradiol on monitoring labs

If Estradiol Remains Elevated

The FDA label notes that during clinical trials, women whose estradiol levels were not reduced to postmenopausal range received two goserelin depots (7.2 mg total dose) 3. Consider:

• Increasing to monthly dosing if using 12-week formulation
• Checking for medication adherence/administration technique
• Considering surgical oophorectomy if medical suppression fails

Bottom Line

Start goserelin immediately. Waiting for FSH/estradiol results provides no clinical benefit and delays essential adjuvant therapy in a high-risk patient. The laboratory values you obtain now (before goserelin) will help establish baseline, but they should not delay treatment initiation. Monitor estradiol levels prior to subsequent goserelin doses to confirm adequate suppression, particularly if you plan to use an aromatase inhibitor.